drugset / Trial / NCT00405080

A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

NCT00405080

Phase 1 Completed 12 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will examine what the body does while taking GW679769 alone and together with rifampin in healthy adult subjects.

Timeline

Start
2006-11-11
Primary completion
2007-01-05
Completion
2007-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Casopitant Small molecule 150 mg Oral
Subject Rifampin Small molecule 600 mg Oral